A Predictive Model for Aggressive Non-Hodgkin's Lymphoma

• Published in: The New England journal of medicine Vol. 329; no. 14; pp. 987 - 994
• Main Authors: Shipp, M A, Harrington, D P, Anderson, J R, Armitage, J O
• Format: Journal Article
• Language: English
• Published: Boston, MA Massachusetts Medical Society 30.09.1993
• Subjects: Age; Age Factors; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Bone marrow; Cancer; Cancer therapies; Chemotherapy; Chromosomes; Classification; Clinical trials; Doxorubicin; Female; Follow-Up Studies; Hematologic and hematopoietic diseases; Humans; L-Lactate dehydrogenase; Lactic acid; Leukemia; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Lymphoma; Lymphoma, Non-Hodgkin - classification; Lymphoma, Non-Hodgkin - drug therapy; Lymphoma, Non-Hodgkin - mortality; Male; Medical prognosis; Medical schools; Medical sciences; Middle Aged; Non-Hodgkin's lymphoma; Oncology; Patients; Prognosis; Regression Analysis; Risk; Risk groups; Survival; Survival Rate; Treatment Outcome; Lebanon; Italy; Ann Arbor Michigan; United States > US; Germany; Nebraska; Human; Malignant hemopathy; Models; Prognosis; Non Hodgkin lymphoma
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJM199309303291402

Combination chemotherapy has transformed aggressive non-Hodgkin's lymphoma from a fatal disease into one that is often curable. However, many patients still die of their disease, underscoring the need for more accurate methods of prospectively identifying patients with different long-term prognoses. The identification of those at “high” or “low” risk could have important therapeutic implications. Patients at high risk who are not effectively treated with current regimens may benefit from new experimental approaches, whereas those at low risk may do well with standard therapy but sustain severe toxic reactions without additional benefit if they are treated with experimental regimens. The identification . . .